Voydeya Dosage
Generic name: Danicopan 100mg
Dosage form: tablet, film coated
Drug class: Selective immunosuppressants
Medically reviewed by Drugs.com. Last updated on Dec 6, 2024.
Recommended Vaccination and Prophylaxis for Encapsulated Bacterial Infections
Vaccinate patients against encapsulated bacteria, including Neisseria meningitidis (serogroups A, C, W, Y, and B) and Streptococcus pneumoniae according to current ACIP recommendations at least 2 weeks prior to initiation of VOYDEYA.
If urgent VOYDEYA therapy is indicated in a patient who is not up to date with vaccines for Neisseria meningitidis and Streptococcus pneumoniae according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.
Healthcare professionals who prescribe VOYDEYA must enroll in the VOYDEYA REMS.
Recommended Dosage
Starting Dose:
The recommended dosage of VOYDEYA is 150 mg three times a day administered orally.
VOYDEYA can be taken with or without food.
Dose Adjustment:
The dose can be increased to 200 mg three times a day if the patient's hemoglobin (Hgb) level has not increased by greater than 2 g/dL after 4 weeks of therapy, if the patient required a transfusion during the previous 4 weeks, or to achieve an appropriate Hgb response based on clinical judgement.
Missed Doses
A patient who misses a dose of VOYDEYA should take it as soon as they remember unless it is within 3 hours prior to their next dose, in which case the patient should skip the missed dose and take VOYDEYA at the next regularly scheduled time. Patients should not take two or more doses of VOYDEYA at the same time.
More about Voydeya (danicopan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Empaveli
Empaveli (pegcetacoplan) is an immunosuppressant that is given by subcutaneous (under the skin) ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
PiaSky
PiaSky (crovalimab-akkz) may be used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Iptacopan
Iptacopan is an oral capsule used to treat paroxysmal nocturnal hemoglobinuria (PNH) or to reduce ...
Pegcetacoplan
Pegcetacoplan (brand name Empaveli) is a twice-weekly, injectable medicine that may be used to ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
